Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
PALSONIFY (PALTUSOTINE HYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
PALSONIFY
NDA
PALTUSOTINE HYDROCHLORIDE | N219070 | CRINETICS PHARMACEUTICALS INC
2 strengths
9 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
VA FSS
Approvals
Label
Products
Patent Timeline
9 unique patents, 2 exclusivities by expiration date
All strengths
EQ 20MG BASE
EQ 30MG BASE
Active (9)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
Today
9896432
Jul. 12, 2037
10351547
Jul. 12, 2037
10464918
Jan. 16, 2039
10597377
Jul. 12, 2037
10875839
Jul. 12, 2037
11266641
Sep. 7, 2041
11414397
Jul. 12, 2037
11957674
Sep. 7, 2041
12208092
Mar. 25, 2044
NCE
Sep. 25, 2030
ODE-537
Sep. 25, 2032
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 20MG BASE
RLD
9 patents
2 exclusivities
▴
TABLET;ORAL | Approved: Sep 25, 2025
Patents (9)
· 8 use codes
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9896432
Jul 12, 2037
—
Yes
Yes
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
10351547
Jul 12, 2037
—
Yes
Yes
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
10464918
Jan 16, 2039
—
Yes
—
—
—
10597377
Jul 12, 2037
—
Yes
Yes
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
10875839
Jul 12, 2037
—
—
—
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
11266641
Sep 7, 2041
—
—
Yes
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
11414397
Jul 12, 2037
—
Yes
Yes
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
11957674
Sep 7, 2041
—
—
—
U-4283
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
12208092
Mar 25, 2044
—
—
—
U-4282
TREATMENT OF ADULTS WITH ACROMEGALY WHO HAVE HEPATIC IMPAIRMENT AND AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
—
Exclusivities (2)
Code
Date
Status
NCE
Sep 25, 2030
Active
ODE-537
Sep 25, 2032
Active
#002 — EQ 30MG BASE
RLD
9 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Sep 25, 2025